Bolt Biotherapeutics, Inc..
BOLT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that harness the power of the immune system to eradicate cancer. The company's lead product candidate is BDC-1001, an ISAC (Immune-Stimulating Antibody Conjugate) designed to target HER2-expres...Show More
Better Health for All
0
No evidence available to assess Bolt Biotherapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Bolt Biotherapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points for BOLT.US were found across the provided articles to assess any of the Fair Pay & Worker Respect KPIs. Information regarding salaries and compensation ratings was available for 'Assemble (PA)', but this is not relevant to BOLT.US.
1
One article mentioned a median CEO salary for Redwood City, CA, but did not provide the median employee compensation for BOLT.US, nor the CEO to median employee pay ratio itself, which is required for scoring that KPI.
2
Fair Trade & Ethical Sourcing
0
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company.
1
The concept of fair-trade certification for physical commodities is not applicable to its operations, as explicitly stated in the provided documents.
2
Honest & Fair Business
0
The provided articles primarily discuss a securities class action lawsuit filed against Bolt Biotherapeutics, Inc. The lawsuit alleges that the company made false and misleading statements about the effectiveness and commercial prospects of its BDC-1001 drug and its overall drug pipeline, as well as misleading statements regarding leadership transitions and workforce reductions.
1
The class period for these allegations is from February 5, 2021, to May 14, 2024.
2
However, the articles do not provide any specific data points or quantitative metrics related to regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy index scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims.
3
Therefore, no KPIs can be scored based on the evidence provided.
Kind to Animals
-40
Bolt Biotherapeutics conducts preclinical laboratory and animal studies, including on non-human primates, as part of its drug development process.
1
These animal studies are required by the FDA before testing product candidates in humans and are subject to federal regulations, including Good Laboratory Practice (GLP) regulations for safety and toxicology studies.
2
The company uses animals for product testing to assess potential adverse events and establish therapeutic rationale, and to show the potential of ISACs to eradicate tumors and induce immunological memory.
3
There is no evidence of a policy that goes beyond meeting these legal mandates or that prohibits discretionary testing.
No War, No Weapons
0
The provided articles do not contain any specific, concrete data points or explicit facts regarding Bolt Biotherapeutics' involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, divestment policies, board oversight of defense activities, export controls, lobbying, procurement standards, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, conflict minerals, or any other metrics related to the 'No War, No Weapons' ethical value. , a financial report for Bolt Biotherapeutics, explicitly states that no data relevant to this value is present.
1
Articles and pertain to other companies' conflict minerals policies and explicitly state they contain no data relevant to Bolt Biotherapeutics.
2
was unavailable.
3
Planet-Friendly Business
0
No evidence available to assess Bolt Biotherapeutics, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points or facts regarding Bolt Biotherapeutics, Inc.'s performance on any of the 'Respect for Cultures & Communities' KPIs were found in the provided articles.
1
The articles either discuss general industry policy, or indicate that data could not be extracted from the specified source.
2
Safe & Smart Tech
0
The provided articles primarily discuss a class-action lawsuit against Bolt Biotherapeutics, Inc. concerning alleged securities fraud related to product effectiveness and commercial prospects.
1
No information or specific data points relevant to data protection, cybersecurity, AI ethics, or privacy practices, which fall under the 'Safe & Smart Tech' value, were found in any of the provided sources.
Zero Waste & Sustainable Products
-10
The company achieved an overall waste diversion rate of 61.21% in 2023, based on diverting 62% of biohazardous waste, 48% of chemical waste, and 71% of plastic materials.
1
Additionally, 83% of its packaging consists of recyclable materials.
2